...
首页> 外文期刊>PDA journal of pharmaceutical science and technology >Development and evaluation of push-pull based osmotic delivery system for pramipexole.
【24h】

Development and evaluation of push-pull based osmotic delivery system for pramipexole.

机译:基于推挽式普拉克索渗透传输系统的开发和评估。

获取原文
获取原文并翻译 | 示例

摘要

An oral push-pull system that can deliver pramipexole for extended period of time has been developed and characterized. A bilayer osmotic drug delivery system was developed using a basic design consisting of an oral controlled porosity osmotic pump. Unlike other osmotic systems, which require a preformed orifice for drug release, controlled porosity membranes contain water-soluble pore-formers in the coating membrane. When such systems come in contact with water, the additives dissolve resulting in an in-situ formation of a microporous membrane. The push layer swells releasing the drug at a controlled rate. In advanced Parkinson's disease the usual dose of pramipexole is 1.5 mg three to four times a day. Hence, an attempt was made to develop a once-a-day controlled release system. This may offer significant patient benefits by providing enhanced efficacy and reduced side effects and may also reduce the number of daily doses compared to conventional therapies. This developed push-pull system was compared with other types of osmotic delivery systems, such as an asymmetric membrane coating and a dense coat with mechanical drilling. An optimized system was selected to study the effect of the concentration of a pore-forming agent such as PEG 400 and dibutyl phthalate, the pH of dissolution media, the effect of agitation and osmotic agents on drug release. The osmotic pressure generated was determined using a 3D3 freezing point osmometer. The drug release was found to follow zero order kinetics. Drug release increased with an increase in osmotic pressure. The developed push-pull osmotic system showed the desired once-a-day release kinetics.
机译:已经开发并表征了可以长时间递送普拉克索的口服推挽系统。使用由口腔控制的孔隙度渗透泵组成的基本设计开发了双层渗透药物递送系统。与其他需要预先设置孔口以释放药物的渗透系统不同,可控孔隙膜在涂层膜中包含水溶性造孔剂。当这样的系统与水接触时,添加剂溶解,导致原位形成微孔膜。推动层膨胀以受控的速率释放药物。在晚期帕金森氏病中,普拉克索的常规剂量为每天三到四次1.5毫克。因此,试图开发每天一次的控释系统。与常规疗法相比,这可以通过提供增强的功效和减少的副作用而为患者带来重大利益,并且还可以减少每日剂量的数量。将此发达的推拉系统与其他类型的渗透传输系统进行了比较,例如不对称膜涂层和带有机械钻孔的致密涂层。选择一个优化的系统来研究成孔剂(例如PEG 400和邻苯二甲酸二丁酯)的浓度,溶出介质的pH值,搅动和渗透剂对药物释放的影响。使用3D3冰点渗透压计测定产生的渗透压。发现药物释放遵循零级动力学。药物释放随着渗透压的增加而增加。发达的推拉式渗透系统显示了所需的每天一次的释放动力学。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号